SCHEMBL6097200

SCHEMBL6097200

Brc1ccccc1COCCOCCOC1CCCCO1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.44
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
TACR1 P25103 1/20 0.38
IDO1 P14902 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CHRM3 P20309 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CARM1 Q86X55 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
RECQL P46063 1/20 0.33
CYP2A13 Q16696 1/20 0.32
SLC6A2 P23975 1/20 0.31
KDM4E B2RXH2 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096051 1.00 KDM4C (0.44) KDM4CKMT2AMEN1TACR1IDO1
SCHEMBL6632939 1.00 KDM4C (0.44) KDM4CKMT2AMEN1TACR1IDO1
SCHEMBL6097349 0.99 KDM4C (0.44) KDM4CKMT2AMEN1TACR1IDO1
SCHEMBL6095923 0.92 MEN1 (0.44) KDM4CKMT2AMEN1TACR1IDO1
SCHEMBL2006340 0.86 TACR1 (0.45) KDM4CKMT2AMEN1TACR1IDO1
SCHEMBL772902 0.84 KDM4C (0.53) KDM4CKMT2AMEN1TACR1L3MBTL1
SCHEMBL18343990 0.83 KDM4C (0.44) KDM4CKMT2AMEN1IDO1L3MBTL1
SCHEMBL31008230 0.81 KDM4C (0.39) KDM4CKMT2AMEN1IDO1L3MBTL1
SCHEMBL27031980 0.81 KDM4C (0.47) KDM4CKMT2AMEN1L3MBTL1NPC1
SCHEMBL21068940 0.80 MEN1 (0.47) KDM4CKMT2AMEN1L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US claimed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US claimed
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF KDM4C 4610/4885KMT2A 4393/4885MEN1 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.